| SC 13D/A | 2024-04-17 | Syntone Ventures LLC | Outlook Therapeutics, Inc. | 2,776,867 | 11.4% | EDGAR |
| SC 13G | 2024-04-08 | GREAT POINT PARTNERS LLC | Outlook Therapeutics, Inc. | 2,231,324 | 10.0% | EDGAR |
| SC 13G | 2024-03-28 | Velan Capital Investment Management LP | Outlook Therapeutics, Inc. | 1,250,000 | 5.6% | EDGAR |
| SC 13G | 2024-03-28 | TANG CAPITAL PARTNERS LP | Outlook Therapeutics, Inc. | 2,215,851 | 10.0% | EDGAR |
| SC 13D/A | 2024-03-20 | GMS Ventures & Investments | Outlook Therapeutics, Inc. | 9,266,645 | 37.0% | EDGAR |
| SC 13D/A | 2024-01-31 | Tenshi Healthcare Pte. Ltd. | Outlook Therapeutics, Inc. | 16,637,024 | 6.4% | EDGAR |
| SC 13D/A | 2023-11-29 | Tenshi Healthcare Pte. Ltd. | Outlook Therapeutics, Inc. | 19,351,493 | 7.4% | EDGAR |
| SC 13G/A | 2023-02-21 | Hope Jason | Outlook Therapeutics, Inc. | 20,000,000 | 7.8% | EDGAR |
| SC 13D/A | 2022-12-29 | GMS Ventures & Investments | Outlook Therapeutics, Inc. | 71,277,519 | 27.9% | EDGAR |
| SC 13D/A | 2022-07-08 | Tenshi Healthcare Pte. Ltd. | Outlook Therapeutics, Inc. | 22,982,529 | 10.2% | EDGAR |
| SC 13D | 2022-07-07 | GMS Ventures & Investments | Outlook Therapeutics, Inc. | 57,047,101 | 25.1% | EDGAR |
| SC 13D/A | 2022-04-22 | BioLexis Pte Ltd. | Outlook Therapeutics, Inc. | 22,982,529 | 10.2% | EDGAR |
| SC 13G | 2022-04-01 | Hope Jason | Outlook Therapeutics, Inc. | 15,012,357 | 6.7% | EDGAR |
| SC 13D/A | 2022-02-01 | BioLexis Pte Ltd. | Outlook Therapeutics, Inc. | 50,965,058 | 22.7% | EDGAR |
| SC 13D/A | 2021-12-01 | BioLexis Pte Ltd. | Outlook Therapeutics, Inc. | 50,965,058 | 22.7% | EDGAR |
| SC 13D/A | 2021-02-05 | Syntone Ventures LLC | Outlook Therapeutics, Inc. | 19,823,045 | 11.7% | EDGAR |
| SC 13D/A | 2021-02-02 | BioLexis Pte Ltd. | Outlook Therapeutics, Inc. | 50,965,058 | 31.4% | EDGAR |
| SC 13G/A | 2021-01-05 | SABBY MANAGEMENT, LLC | Outlook Therapeutics, Inc. | 133,818 | 0.1% | EDGAR |
| SC 13D | 2020-06-12 | Syntone Ventures LLC | Outlook Therapeutics, Inc. | 16,000,000 | 14.9% | EDGAR |
| SC 13D/A | 2020-03-24 | BioLexis Pte Ltd. | Outlook Therapeutics, Inc. | 50,965,058 | 61.8% | EDGAR |